Sanctuary Advisors LLC Purchases New Shares in AtriCure, Inc. $ATRC

Sanctuary Advisors LLC bought a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) during the second quarter, Holdings Channel.com reports. The fund bought 17,515 shares of the medical device company’s stock, valued at approximately $490,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of America Corp DE grew its position in shares of AtriCure by 13.7% in the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock worth $21,927,000 after buying an additional 92,830 shares during the period. Assenagon Asset Management S.A. purchased a new stake in AtriCure during the 2nd quarter valued at $1,744,000. Rice Hall James & Associates LLC purchased a new stake in shares of AtriCure during the second quarter valued at $3,755,000. F m Investments LLC bought a new stake in shares of AtriCure in the fourth quarter worth approximately $2,872,000. Finally, Vanguard Group Inc. grew its position in AtriCure by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after purchasing an additional 62,861 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at AtriCure

In other news, Director Karen Prange sold 3,564 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director directly owned 22,809 shares in the company, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sven Wehrwein sold 25,000 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the sale, the director directly owned 40,518 shares in the company, valued at $1,533,201.12. This trade represents a 38.16% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 53,616 shares of company stock worth $2,149,994. Insiders own 4.00% of the company’s stock.

AtriCure Trading Down 1.5%

ATRC stock opened at $48.54 on Friday. The firm’s 50-day moving average is $37.89 and its 200 day moving average is $32.26. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $49.98. The company has a market capitalization of $2.47 billion, a PE ratio of 231.15 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts anticipate that AtriCure, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Piper Sandler increased their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday. Raymond James Financial set a $52.00 target price on AtriCure in a research report on Tuesday, July 21st. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. BTIG Research upped their price objective on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Finally, UBS Group dropped their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $49.89.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.